Earnings call transcript: Uniphar H1 2026 profit rises as growth plan stays on track

Uniphar reported H1 2026 adjusted EPS growth of 11.2% to EUR 0.109, gross profit growth of 7.7% to EUR 236.5 million, and EBITDA growth of 6.2% to EUR 61.1 million. Management reaffirmed its EUR 200 million EBITDA target for 2028, supported by expected double-digit Pharma growth and high-single-digit Medtech growth, while shares rose 1.32% to $4.23. Offsetting the solid operating performance, free cash flow was negative EUR 47 million due to an EUR 86.5 million working-capital outflow, and the Greenogue 2 distribution-center launch was delayed to February 2027 with roughly EUR 20 million of incremental capex.

Analysis

UPR’s investable inflection is not the reported earnings beat but whether its infrastructure spend converts into operating leverage after 2027. The company is effectively carrying excess fixed-cost capacity today; if Pharma commercialization mandates and Medtech geographic extensions fill that capacity, incremental gross profit should convert at materially higher rates than the current group margin. This favors a 6-18 month multiple re-rating toward specialty-services peers rather than a near-term earnings trade, provided management can demonstrate cash conversion without further balance-sheet expansion.

The key near-term issue is that working capital is structurally less predictable in global sourcing and expanded-access activities than management’s normalized-conversion framing implies. At leverage near its stated ceiling, another cash shortfall would constrain bolt-on M&A precisely when smaller biotech and carved-out medtech portfolios may create attractive acquisition opportunities. There is also a credibility issue in the disclosed divisional EBITDA figures, which contain an apparent Medtech inconsistency; investors should require reconciliation before underwriting margin progression.

Competitive spillover for PHG and SYK is modest but directionally relevant: continued outsourcing by device manufacturers supports European third-party commercialization platforms, though UPR’s success would be more a function of execution in fragmented subscale markets than a broad demand surge. The contrarian view is that the Greenogue transition may be worth more as a defensive service-continuity and customer-retention asset than as an immediate cost-savings event; expectations for a sharp post-launch margin step-up should therefore be tempered.

Immediate upside is likely limited absent consensus-estimate revisions, but the 1-3 month catalyst path is evidence of H2 Pharma acceleration, new client go-lives, and a clean clarification of cash-flow mechanics. The thesis is falsified by another facility delay, sustained conversion below 50% through FY27, net leverage above 2.5x without a clearly accretive acquisition, or failure of Pharma gross-profit growth to outpace its investment base.

Key Decisions for Investors

• Watch-list UPR for a staged long rather than chase the current reaction; initiate only after FY26 cash conversion and leverage guidance confirm no further balance-sheet pressure. Target a 12-18 month holding period through the Greenogue ramp, with risk capped if FY27 conversion guidance falls below 60% or net leverage exceeds 2.5x.
• For existing UPR holders, maintain a core position but do not add on EBITDA guidance alone; demand disclosure reconciling Medtech EBITDA and a quantified bridge from facility capacity to savings/revenue. A clean reconciliation plus H2 gross-profit acceleration would be a 1-3 month add catalyst.
• Avoid using SYK or PHG as direct read-through longs: UPR’s outsourcing momentum is too small relative to their consolidated earnings bases. Use any sector strength instead as confirmation of the European medtech outsourcing backdrop, not as a standalone trade signal.
• Monitor UPR’s spread versus European healthcare-services peers after the next results: a de-rating despite stable operational execution could create the better entry point, because the central uncertainty is cash timing and execution, not end-market demand.